SEC Company Response from Eledon Pharmaceuticals, Inc. (ELDN) (CIK 0001404281) (ELDN) — Jun 3, 2024

Eledon Pharmaceuticals, Inc. (ELDN) (CIK 0001404281)
Date: June 3, 2024 · CIK: 0001404281 · Accession: 0000950170-24-067759

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-279711

Date

June 3, 2024

Author

Paul Little

Form

CORRESP

Company

Eledon Pharmaceuticals, Inc. (ELDN) (CIK 0001404281)

Letter

VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Lauren Hamill Registration Statement on Form S-3 (File No. 333-279711)

Re: Request for Effectiveness for Eledon Pharmaceuticals, Inc.

Dear Ms. Hamill:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Eledon Pharmaceuticals, Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the above-referenced Registration Statement be accelerated to 10:00 a.m. Eastern Time, on Wednesday, June 5, 2024, or as soon thereafter as practicable. The Registrant respectfully requests that you notify Shelly Heyduk of O’Melveny & Myers LLP of such effectiveness by telephone at (949) 823-7968.

If you have any questions or comments regarding the foregoing, please do not hesitate to contact Ms. Heyduk at the telephone number above.

Very truly yours,
Eledon Pharmaceuticals, Inc.

Show Raw Text

CORRESP
1
filename1.htm

  CORRESP

  June 3, 2024

  VIA EDGAR

  Division of Corporation Finance

  Office of Life Sciences

  United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-3628

  Attention: Lauren Hamill

  Re:	Request for Effectiveness for Eledon Pharmaceuticals, Inc.

  		Registration Statement on Form S-3 (File No. 333-279711)

  Dear Ms. Hamill:

  Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Eledon Pharmaceuticals, Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the above-referenced Registration Statement be accelerated to 10:00 a.m. Eastern Time, on Wednesday, June 5, 2024, or as soon thereafter as practicable. The Registrant respectfully requests that you notify Shelly Heyduk of O’Melveny & Myers LLP of such effectiveness by telephone at (949) 823-7968.

  If you have any questions or comments regarding the foregoing, please do not hesitate to contact Ms. Heyduk at the telephone number above.

  Very truly yours,

  Eledon Pharmaceuticals, Inc.

  By: /s/ Paul Little

         Name:   Paul Little

         Title:     Chief Financial Officer

  cc:	Shelly Heyduk, O’Melveny & Myers LLP

SecProbe.io